BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

  June 2, 2025

   · 

  16 min read
• Press Releases

  bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

  June 2, 2025

   · 

  6 min read
• Press Releases

  Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

  June 2, 2025

   · 

  8 min read
• Press Releases

  Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

  June 2, 2025

   · 

  2 min read
• Press Releases

  Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations at the GBA1 Meeting 2025

  June 2, 2025

   · 

  2 min read
• Press Releases

  ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

  June 2, 2025

   · 

  15 min read
• Press Releases

  UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

  June 2, 2025

   · 

  7 min read
• Press Releases

  Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

  June 2, 2025

   · 

  1 min read
• Press Releases

  Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

  June 2, 2025

   · 

  7 min read
• Press Releases

  Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease

  June 2, 2025

   · 

  3 min read